Stockscreener 앱 받기
3.25
0.31%
0.010
시간 외 거래:
3.29
0.04
+1.23%
전일 마감가:
$3.24
열려 있는:
$3.25
하루 거래량:
2.50M
Relative Volume:
0.61
시가총액:
$707.53M
수익:
$35.54M
순이익/손실:
$-59.14M
주가수익비율:
-8.9359
EPS:
-0.3637
순현금흐름:
$-80.19M
1주 성능:
-7.67%
1개월 성능:
-4.41%
6개월 성능:
-45.19%
1년 성능:
+35.42%
1일 변동 폭
$3.25
$3.43
1주일 범위
$3.20
$3.545
52주 변동 폭
$1.72
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
3.25 | 705.36M | 35.54M | -59.14M | -80.19M | -0.3637 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2026-01-20 | 개시 | Guggenheim | Buy |
| 2025-09-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
BlackRock (CTMX holder) discloses 7.6% beneficial stake in CytomX Therapeutics - Stock Titan
CytomX Therapeutics Inc (CTMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CytomX appoints Charles Fuchs to board of directors By Investing.com - Investing.com Canada
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors - The Manila Times
Charles Fuchs appointed to CytomX Board as Class II director - TradingView
More Than Three Decades in Oncology: Fuchs Joins CytomX Board - Stock Titan
CytomX Therapeutics Inc (CTMX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CytomX Therapeutics Inc (CTMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CTMX|CytomX Therapeutics Inc|Price:3.240|Chg%:-0.090 - TradingKey
TradingKey - TradingKey
CytomX Therapeutics Inc (CTMX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CTMX stock holds focus after CytomX strategy update - Ad-hoc-news.de
CytomX Therapeutics, Inc.Common Stock (NQ: CTMX - FinancialContent
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits
CytomX Therapeutics (CTMX) Holds Near Support After Slight DipUpthrust Pattern - dars.gov.et
CytomX Therapeutics updates investors on its pipeline progress amid Nasdaq listing - Ad-hoc-news.de
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why - Yahoo Finance
CytomX Therapeutics focuses on its antibody-drug conjugate platform - Ad-hoc-news.de
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - Yahoo Finance
CytomX Therapeutics outlines its oncology focus as investors watch Nasdaq trading - ad-hoc-news.de
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits
CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Value Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to Russell Microcap Value Benchmark Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Growth Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell Microcap Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Growth Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000 Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000 Growth Benchmark - marketscreener.com
Price to book forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Price to earnings forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Enterprise value to EBIT forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Price to sales forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Enterprise value to revenue forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
CytomX Therapeutics, Inc. Actuals & Estimates (NASDAQ:CTMX) - TradingView
CTMX Forecast — Price Target — Prediction for 2027 - TradingView
CytomX Shareholders Approve Expanded Equity and Capital Plans - The Globe and Mail
Form 4 CytomX Therapeutics Inc For: 22 June By Investing.com - Investing.com India
CytomX Therapeutics Amends Equity Incentive and Employee Stock Purchase Plans Following 2026 Shareholder Approval – Minichart - Minichart
CytomX Therapeutics stockholders approve share increases and board elections - Investing.com
CytomX Therapeutics stockholders approve share increases and board elections By Investing.com - Investing.com Canada
Form 8K CytomX Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
CytomX (CTMX) director Su Zhen awarded 59,000 stock options at $2.96 - Stock Titan
[8-K] CytomX Therapeutics, Inc. Reports Material Event - Stock Titan
Director at CytomX (NASDAQ: CTMX) awarded 59,000 stock options - Stock Titan
Director at CytomX (NASDAQ: CTMX) receives 59,000-stock option award - Stock Titan
CytomX (CTMX) director receives 59,000 stock options at $2.96 - Stock Titan
CytomX (CTMX) director Halley Gilbert receives 59,000 stock options at $2.96 strike - Stock Titan
CytomX (CTMX) director Alan Ashworth receives grant of 59,000 stock options - Stock Titan
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):